Cyclin-dependent kinases as signaling integrators in cancer: Structural evolution, functional plasticity, and drug...

Cyclin-dependent kinases (CDKs), traditionally recognized for their pivotal role in cell cycle control, have emerged as versatile regulators orchestrating a broader spectrum of biological functions, including transcriptional regulation, immune signaling, metabolic adaptation, and neuronal activity. This review provides a comprehensive synthesis of the structural, functional, and pharmacological landscapes of the CDK family, emphasizing their evolutionary diversification and expanding therapeutic relevance. We explored the conserved architecture of CDK catalytic cores and delineated isoform-specific regulatory adaptations that have evolved through gene duplication and sequence divergence. These evolutionary modifications have enabled the functional repurposing of CDKs across eukaryotic species, which play critical roles in immune modulation, metabolic control, and synaptic plasticity. We also analyzed activation mechanisms, cyclin-binding interfaces, and substrate-recognition features that govern CDK activity. We then examine the pathological consequences of CDK dysregulation in oncogenesis, neurodegeneration, and autoimmune disorders with a focus on drug resistance in current clinical approaches. We further highlighted emerging therapeutic strategies, including transcription-targeting CDK inhibitors, proteolysis-targeting chimeras (PROTACs), covalent inhibitors, and artificial intelligence-guided drug discovery platforms that promise to overcome these challenges. Special attention is given to understudied and emerging CDKs, notably CDK11 (cancer), CDK14 (development), and CDKL5 (neurodegeneration), which represent untapped therapeutic frontiers with disease-specific relevance. Collectively, this review repositions CDKs as cell cycle regulators and central signaling integrators within complex disease networks. We propose a structural and mechanistic framework to guide the rational targeting of CDKs in the precision medicine era, paving the way for the next generation of kinase-based therapeutics.